Clinical study of AdV-tk radiogene therapy for glioma

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R44CA107745-01
Agency Tracking Number: CA107745
Amount: $758,386.00
Phase: Phase I
Program: SBIR
Awards Year: 2004
Solicitation Year: 2004
Solicitation Topic Code: N/A
Solicitation Number: PHS2004-2
Small Business Information
ADVANTAGENE, INC., 160 PAULSON RD, WABAN, MA, 02468
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 ESTUARDO Aguilarcordova
 (617) 916-5445
 EAGUILAR@ADVANTAGENE.COM
Business Contact
 AMANDA DAVIS
Phone: (617) 916-5445
Email: ADAVIS@ADVANTAGENE.COM
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease with great need of novel therapeutic approaches. Within cancer gene therapy the use of adenovir

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government